Blood tests for Alzheimer's disease are entering clinical practice and reshaping how doctors diagnose the condition before symptoms appear. Researchers presented new validation data at the Alzheimer's Association International Conference in London, demonstrating that these tests detect key biomarkers in the bloodstream with high accuracy.
The tests measure phosphorylated tau and amyloid-beta levels, proteins that accumulate in the brains of Alzheimer's patients years before memory loss begins. Unlike PET scans and cerebrospinal fluid tests, blood tests are noninvasive, affordable, and scalable across healthcare systems. This matters because early detection allows patients to access new disease-modifying treatments like lecanemab and donanemab, which slow cognitive decline when administered early.
The blood tests show several advantages over traditional diagnostic methods. They require only a simple draw and deliver results within days. They identify people with cognitive decline who have underlying Alzheimer's pathology, helping distinguish Alzheimer's from other dementias. This precision prevents misdiagnosis and connects patients to appropriate care earlier.
Limitations exist. Blood tests cannot replace cognitive assessment or rule out other causes of memory problems. They work best in people already showing some cognitive symptoms or at high genetic risk, not as universal screening tools. Cost and insurance coverage remain uncertain in many regions. Standardization across different labs and test manufacturers is still developing.
The tests represent a shift from waiting for dementia symptoms to treating people during the preclinical phase when interventions may be most effective. This approach depends on informed consent and genetic counseling, since results can be psychologically difficult for asymptomatic carriers of Alzheimer's pathology.
Researchers emphasize that blood tests should complement, not replace, clinical evaluation by specialists trained in dementia diagnosis. Access remains uneven globally, with tests primarily available in wealthy countries. As the population ages and Alz